Cargando…
Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
Most patients with advanced melanoma ultimately fail immune checkpoint inhibitor (ICI) therapy because of primary or acquired resistance. There remains a critical unmet need for new therapies that function via alternative immune activation mechanisms to safely trigger an antitumor immune response in...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314703/ https://www.ncbi.nlm.nih.gov/pubmed/34312244 http://dx.doi.org/10.1136/jitc-2021-002820 |